To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
12 Current news of BioNTechrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Regulatory Approval From Paul-Ehrlich-Institut to Commence German Part of Global Phase 2/3 Trial Received
BioNTech SE and Pfizer Inc. announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 2/3 clinical trial in Germany for their BNT162b2 vaccine candidate. The study in Germany is part of the global pivotal Phase 2/3 program BioNTech and Pfizer initiated in ...
Doses expected to be delivered in 2020 and 2021
Pfizer Inc. and BioNTech SE announced an agreement with the United Kingdom to supply 30million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not ...
Efforts to manufacture the leading candidates, at risk, are gearing up
Pfizer Inc. and BioNTech SE announced preliminary U.S. data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at ...
The private placement includes an investment in ordinary shares and a investment in 4-year mandatory convertible notes
BioNTech SE announced a private investment of USD 250 million (EUR 223 million) by Temasek and other accredited investors. The private placement includes an investment of approximately USD 139 million in ordinary shares and a USD 112 million investment in 4-year mandatory convertible notes. “We ...
BioNTech SE and Pfizer Inc. disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020. The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on ...
Pfizer Inc. and BioNTech SE announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and ...
One of the largest private EU biotech funding events expands global shareholder base
BioNTech SE announced the completion of a USD 325 million Series B financing round, making it one of the largest single private funding rounds for a biotechnology company in European history. The fund raising was upsized and was led by Fidelity Management & Research Company with participation ...
BioNTech AG announced that it has extended its research collaboration with Sanofi initiated in late 2015 and Sanofi is investing* EUR 80 million (approximately USD 91.5 million) in equity in BioNTech. Simultaneously BioNTech has entered into an agreement with Sanofi to co-develop the first cancer ...
BioNTech AG announced it has completed a USD 270 million Series A round of financing. The Company previously completed a seed round fundraising in 2008 concurrent with its founding. The Series A round was led by the Redmile Group and joined by Janus Henderson Investors, Invus, Fidelity Management ...
Contains license agreement for cancer immunotherapy
Sanofi and BioNTech A.G. announced that they have entered into a multiyear exclusive collaboration and license agreement. This research collaboration between Sanofi and BioNTech will leverage the scientific expertise of the two organizations to discover and develop up to five cancer ...